Oral ATP (Adenosine Triphosphate) and absorption

What 2 graded rows on oral atp (adenosine triphosphate) agree on for absorption, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Oral ATP (Adenosine Triphosphate) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Oral ATP (Adenosine Triphosphate) page, with its PubMed record.

Supplement

Oral ATP (Adenosine Triphosphate) Choose another

2 rows · 40 people

They agree: both rows found no difference.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

Every row is graded No effect, our grade for adequately powered trials that found no effect.

The rows run from 8 to 32 people, published from 2011 to 2012: 2 single studies.

2 no difference

No effectBlood ATP after 4 weeks of daily dosing · No difference
RCT · n 32 · 2011 · Thirty-two healthy subjects
0, 250, 1250 or 5000 mg a day · 28 days
Blood and plasma ATP did not change; only plasma uric acid rose, after 5000 mg; liver and kidney markers stayed normal.
Row on the Oral ATP (Adenosine Triphosphate) page · PubMed 21129239 (opens PubMed)
No effectBlood ATP after a single large dose · No difference
Crossover RCT · n 8 · 2012 · Eight healthy volunteers
5000 mg once · Single doses
Blood ATP did not rise by any route; uric acid, ATP's end product, rose by ~50% vs placebo with proximal-release pellets.
Row on the Oral ATP (Adenosine Triphosphate) page · PubMed 22510240 (opens PubMed)